shortage tirzepatide FDA says is over after taking a second look The FDA says it's standing

New research is showing real, measurable benefits, and in late 2024 the FDA approved a related GLP-1 drug specifically for the condition

From the phase 3 trials at the 9 mg and 12 mg doses: Nausea: 38.1% (9 mg) to 43.2% (12 mg) versus 10.7% with placebo Diarrhea: 34.7% (9 mg) to 33.1% (12 mg) versus 13.4% with placebo Constipation: 21.8% (9 mg) to 25.0% (12 mg) versus 8.7% with placebo Vomiting: 20.4% (9 mg) to 20.9% (12 mg) Compare those numbers to Mounjaro and the difference is clear

, , ,

Our LED phototherapy sessions are comfortable, deeply relaxing and super-safe and are great to enhance our radiofrequency/ultrasound treatments for skin tightening / cellulite reduction